SECONDARY OBJECTIVES: I. To study additional antitumor activity endpoints of CD19R(EQ)28zeta/EGFRt+ TCM and CD19R(EQ)28zeta/EGFRt+ TN/NEM. II. To explore the efficacy of infusional cetuximab to eliminate transferred CD19R(EQ)CD28zeta/EGFRt+ TCM and CD19R(EQ)28zeta/EGFRt+ TN/NEM.